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Increased prevalence of hyperhomocysteinemia in cervical artery
dissection causing stroke: a case-control study
Abstract
BACKGROUND: Spontaneous cervical artery dissection (sCAD) is a nonatherosclerotic vascular
disease of unknown etiology. Mild elevation of total plasma homocysteine (tHcy) levels may be a risk
factor for sCAD, but the precise mechanism remains unknown. On the other hand, mild
hyperhomocysteinemia is also associated with ischemic stroke related to atherothrombotic or small
artery disease. We undertook a case-control study to compare the prevalence of mild
hyperhomocysteinemia and tHcy levels between patients with a first ischemic stroke due to sCAD and
healthy volunteers, as well as patients with a first ischemic stroke due to atherothrombotic or small
artery disease. METHODS: Fasting tHcy levels were determined in 346 consecutive patients with a first
ischemic stroke due to sCAD (n = 86) and atherothrombotic or small artery disease (n = 260) within 24
h after the onset of symptoms, and in 100 healthy volunteers. RESULTS: Mild hyperhomocysteinemia
was more prevalent in patients with sCAD causing ischemic stroke (n = 33, 38%) than in healthy
volunteers (n = 23, 23%; p = 0.034), and less prevalent than in patients with ischemic stroke due to
atherothrombotic or small artery disease (n = 149, 57%; p = 0.001). Mean fasting tHcy levels of patients
with ischemic stroke caused by sCAD showed a trend to be higher (11.4 +/- 3.8 micromol/l) than those
of healthy volunteers (10.2 +/- 3.0 micromol/l, p = 0.61), but were lower than those of patients with
stroke due to atherothrombotic or small artery disease (13.6 +/- 6.6 micromol/l, p = 0.002).
CONCLUSION: Our results suggest that mild hyperhomocysteinemia may be a risk factor for sCAD
causing ischemic stroke, but further studies are needed to identify a possible mechanism. This study
confirms the association of hyperhomocysteinemia with ischemic stroke due to atherothrombotic or
small artery disease.
Increased Prevalence of Hyperhomocysteinemia in Cervical Artery Dissection 
Causing Stroke. A Case-Control Study. 
 
 
 
David H. Benninger, MD1, François R. Herrmann, MD, MPH2, Dimitri Georgiadis, MD1, 
Robert Kretschmer3, Hakan Sarikaya, MD1, Andreas Schiller, MD1, Ralf W. Baumgartner, MD1
 
 
 
Departments of Neurology, University Hospital of Zürich1, and of Rehabilitation and Geriatrics, 
University Hospital of Geneva2, Institute of Clinical Chemistry, Inselspital, University of 
Berne3, Switzerland 
 
 
Search Headings: Cerebrovascular Disease/Stroke   Cervical Artery Dissection   Risk factor 
Homocysteine 
 
 
2323 words 
 
Correspondence to: Ralf W. Baumgartner MD, Department of Neurology, University Hospital, 
       Frauenklinikstr. 26, 8091 Zürich, Switzerland 
       Phone: 0041/44/255 56 86, Fax: 0041/44/255 88 64,  
E-Mail: ralf.baumgartner@usz.ch  
 1
Abstract 
Background: Spontaneous cervical artery dissection (sCAD) is a non-atherosclerotic vascular 
disease of unknown etiology. Mild elevation of total plasma homocysteine (tHcy) levels may be 
be a risk factor for sCAD, but the precise mechanism remains unknown. On the other hand, mild 
hyperhomocysteinemia is also associated with ischemic stroke related to atherothrombotic or 
small artery disease. We undertook a case-control study to compare the prevalence of mild 
hyperhomocysteinemia and tHcy levels between patients with a first ischemic stroke due to 
sCAD and healthy volunteers as well as patients with a first ischemic stroke due to 
atherothrombotic or small artery disease. 
Methods: Fasting tHcy levels were determined in 346 consecutive patients with a first ischemic 
stroke due to sCAD (n=86) and atherothrombotic or small artery disease (n=260) within 24 
hours after the onset of symptoms, and in 100 healthy volunteers. 
Results: Mild hyperhomocysteinemia was more prevalent in patients with sCAD causing 
ischemic stroke (n=33, 38%) than in healthy volunteers (n=23, 23%; p=0.034), and less 
prevalent than in patients with ischemic stroke due to atherothrombotic or small artery disease 
(n=149, 57%; p=0.001). Mean fasting tHcy levels of patients with ischemic stroke caused by 
sCAD showed a trend to be higher (11.4 ± 3.8 µmol/L) than those of healthy volunteers (10.2 ± 
3.0 µmol/L, p=0.61), but were lower than those of patients with stroke due to atherothrombotic 
or small artery disease (13.6 ± 6.6 µmol/L, p=0.002). 
Conclusion: Our results suggest that mild hyperhomocysteinemia may be a risk factor for 
sCAD causing ischemic stroke, but further studies are needed to identify a possible mechanism. 
This study confirms the association of hyperhomocysteinemia with ischemic stroke due to 
atherothrombotic or small artery disease.  
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Introduction 
Spontaneous cervical artery dissection (sCAD) is a major cause of ischemic stroke in young 
adults 1,2, but the pathogenesis of this disease remains poorly understood. Case-control studies 
reported a significant association of sCAD with total plasma homocysteine (tHcy) 3-5 and the TT 
methylenetetrahydrofolate reductase (MTHFR) genotype, which predisposes to 
hyperhomocysteinemia 5,6. Mild hyperhomocysteinemia is also a risk factor for ischemic stroke 
7, probably by enhancing the development of atherosclerosis in large 8 and small 9,10 cerebral 
arteries. In contrast, patients with sCAD typically have no or minimal atherosclerosis, and are 
not known to have small artery disease 11,12. Therefore, these findings suggest that mild 
hyperhomocysteinemia may predispose to sCAD and also to ischemic stroke due to 
atherothrombotic or small artery disease. 
We undertook this case-control study to compare the prevalence of mild hyperhomocysteinemia 
and tHcy levels between patients with sCAD causing a first ischemic stroke and (1) healthy 
volunteers, and (2) patients with a first ischemic stroke due to atherothrombotic or small artery 
disease.  
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Methods 
Patients and healthy volunteers 
Patients were taken from the Zurich Stroke Data Bank 13, and recruitment period lasted from 
January 1999 until December 2004. Patients were included if (1) they had had a first ischemic 
stroke due to sCAD diagnosed as reported below or due to atherothrombotic or small artery 
disease according to the criteria of TOAST 14, and (2) tHcy levels were determined within 24 
hours after the onset of stroke symptoms as levels progressively increase in the acute phase of 
stroke 15. The local ethics committee had approved the protocol. All patients had undergone a 
thorough evaluation, which included the assessment of the medical history, medical and 
neurological examination, risk factors for ischemic stroke as mentioned below, routine blood 
examinations, 12-lead ECG, extracranial, transorbital and transcranial color duplex sonography 
(CDS), and brain CT or MRI, or both 13. SCAD was detected using cervical MRI and magnetic 
resonance angiography or digital subtraction angiography, or both 16. A sCAD was diagnosed 
when a string sign, an intimal flap or a pseudoaneurysm was identified at angiography, a wall 
hematoma at cervical or cerebral MRI, or both 16. Echocardiography, 24-hour ECG and 
additional laboratory analyses were performed if the treating physician deemed them necessary. 
The following stroke risk factors were differentiated: Current cigarette smoking that included by 
definition cigarette smoking within the last five years 17; former cigarette smoking defined as 
abstention from cigarette smoking that started more than five years ago 17; arterial hypertension 
defined as a history of hypertension or the use of antihypertensive drugs, or both; diabetes 
mellitus defined as a history of diabetes mellitus, fasting venous plasma glucose concentration 
of ≥7.8 mmol/l on at least two separate occasions, or venous plasma glucose concentration 
following the ingestion of 75 g of glucose of ≥11.1 mmol/L at 2 h and at one other occasion 
during the 2-h test; hypercholesterolemia defined as a total venous plasma cholesterol level 
above 5.0 mmol/L; abnormal high-density lipoprotein (HDL) cholesterol defined as values 
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below 1.0 mmol/L, abnormal low-density lipoprotein (LDL) cholesterol defined as values above 
3.0 mmol/L; abnormal ratio total cholesterol / HDL cholesterol defined as values above 5, and 
abnormal triglyceride levels defined as values above 1.6 mmol/L; history of migraine with aura. 
 Healthy volunteers (n=100, 50 men; mean age 43.6 ± 13.1 years, range 20-68) were blood 
donors who were selected after exclusion of a multitude of diseases precluding blood donation 
by rigorous screening according to the published standards of the Swiss Red Cross 
(http://www.zhbsd.ch/index2.htm) also to provide more recent reference values of homocysteine 
plasma levels for clinical purposes. 
 
Determination of fasting tHcy levels 
The fasting levels of tHcy were determined in stroke patients within 24 hours after the onset of 
symptoms and in healthy volunteers with an immunoassay that uses sample pre-treatment and 
monoclonal mouse antibodies (IMMULITE 2500, Abbott IMX). Hyperhomocysteinemia was 
defined as fasting tHcy levels above12.0 µmol/l. 
 
Statistics 
Normality of data distribution was checked with skewness and kurtosis tests. Unpaired t-tests 
were used to compare parametric data between (1) patients with sCAD and (2) patients with 
atherothrombotic or small artery disease. Chi-square tests or Fisher exact test were used to 
compare nominal data. Logistic regression models were performed to evaluate the association 
between tHcy levels and (1) patients with sCAD and (2) patients with atherothrombotic or small 
artery disease (considered either as a continuous or as a binary variable with an increased level 
defined at ≥12 µmol/l) while adjusting for 12 covariates (sex, age, current and past smoking, 
hypertension, diabetes mellitus, hypercholesterolemia, decreased HDL cholesterol levels, 
increased LDL cholesterol levels, increased total cholesterol / HDL cholesterol ratio, increased 
triglyceride levels, migraine with aura). Current antiplatelet or anticoagulant therapy was not 
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considered in the analysis, as no influence on tHcy levels has been proven 5. Analysis of 
covariance was used to compare tHcy levels among (1) patients with sCAD, (2) patients with 
atherothrombotic or small artery disease and (3) healthy controls while adjusting for age and 
gender. Bonferroni correction was applied in multiple group comparison.  
Sensitivity analysis was also applied to find the best discriminating threshold value of tHcy for 
predicting sCAD. Statistical analysis was carried out with Stata, release 9.2 (College Station, 
TX).
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Results 
Six hundred and sixty-eight consecutive patients (445 men; mean age 62.5 ± 13.6, range 20-90 
years) had a first-ever ischemic stroke due to sCAD (n=108) or atherothrombotic or small artery 
disease (n=560). All 344 (52%) of the 668 patients who presented within 24 hours after the 
onset of symptoms (235 men; mean age 60.5 ± 13.8, range 20-87 years; sCAD, n=86, 80%; 
atherothrombotic or small artery disease, n=260, 46%) were included in the study. The 
remaining 322 (48%) patients presented after 24 hours. Their presenting characteristics (Table 
1) did not differ from those of the study population with the exception of a higher mean age 
(64.6 ± 13.2, range 22-90 years; p=0.0001) and frequency of diabetes mellitus (20.0 vs. 11.3%, 
p= 0.002), and a lower frequency of sCAD (6.8 vs. 24.9%; p<0.001).   
The 86 patients (58 men; mean age 46.1 ± 10.4, range 20-68 years) with stroke due to sCAD had 
68 dissections of the internal carotid artery (sICAD) and 24 dissections of the vertebral artery 
(sVAD). SCAD included unilateral sICAD in 64 patients, unilateral recurrent sICAD in one 
patient, unilateral sVAD in 15 patients, bilateral sVAD in three patients, and both sICAD and 
sVAD in three patients. In the 260 patients (177 men; mean age 65 ± 11, 35-90 years) with 
stroke due to atherothrombotic or small artery disease, etiology of stroke was atherothrombotic 
artery disease in 158 (60.8%) and small artery disease in 102 (39.2%).  
Compared to patients with atherothrombotic or small artery disease (Table 1), those with sCAD 
were younger, had a higher prevalence of migraine with aura, a lower prevalence of former 
smokers, hypertension and diabetes mellitus, lower triglyceride levels, and higher HDL 
cholesterol levels. 
Hyperhomocysteinemia and tHCy levels. Hyperhomocysteinemia was more prevalent in 
patients with sCAD (n=33, 38%) than in healthy volunteers (n=23, 23%; p= 0.034), and less 
prevalent than in patients with atherothrombotic or small artery disease (n=149, 57%; p=0.001). 
Total Hcy levels of patients with sCAD causing stroke (11.4 ± 3.8 µmol/l) were (1) higher than 
in healthy volunteers (10.2 ± 3.0 µmol/l), but this difference was not significant (p=0.61), and 
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(2) lower than in patients with stroke due atherothrombotic or small artery disease (13.6 ± 6.6 
µmol/l, p=0.002; crude odds ratio (OR) 0.92, 95% confidence interval (CI) 0.87-0.97, p=0.002) 
which remained significant after adjusting for age and sex (adjusted OR 0.89, 95% CI 0.81-0.98, 
p=0.019; Table 1).  
Considering all patients, increasing tHcy levels showed a weak association with stroke due to 
atherothrombotic or small artery disease (R2=0.029; p=0.002), age (R2=0.026; p=0.003) and 
male gender (R2=0.025; p<0.004). In multiple regression analysis, just the weak association with 
sex remained significant (R2=0.062; p=0.0011). 
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Discussion 
 In the present case-control study, we found that patients with ischemic stroke due to sCAD 
had (1) a higher prevalence of mild hyperhomocysteinemia but similar tHcy levels compared to 
healthy volunteers, and (2) a lower prevalence of mild hyperhomocysteinemia and lower tHcy 
levels than patients with ischemic stroke caused by atherothrombotic or small artery disease, 
also after adjustment for age. 
 Prevalence of mild hyperhomocysteinemia was lower in the present patients with ischemic 
stroke due to sCAD (38%) compared to previous studies reporting values of 57 to 92% 3-5. An 
explanation could be that the prevalence of mild hyperhomocysteinemia varies according to the 
geographical area and ethnic background of the population under investigation. However, a 
similar prevalence of mild hyperhomocysteinemia in the control groups of the present study 
(23%) and previous investigations (14-27%) 4,5 counters this argument. Another explanation of 
those differences could be that tHcy levels have been shown to increase on the third and 
subsequent days after a stroke 15. Blood samples for determining tHcy levels were obtained in 
the present study within 24 hours after the onset of stroke symptoms, while in the 2 of 3 studies 
demonstrating a higher tHcy levels 3,5, they were taken within 3 5 and 7 3  days after the onset of 
the stroke . In the third study 4, blood samples were taken at a median delay of 833 days after the 
onset of sCAD symptoms. Lindgren et al. 18 reported an increase in median tHcy level from 11.4 
to 14.5 µmol/L from the acute (mean 2 days after stroke onset) to the chronic phase (median 583 
days after stroke onset). Thus, the later blood sampling might explain the higher tHcy values and 
prevalence of mild hyperhomocysteinemia reported in previous studies 3-5. Another cause of the 
difference in prevalence might be the low number of included patients with sCAD (Table 2) 3-5. 
 Total Hcy levels were higher in patients with sCAD than in healthy volunteers, although the 
difference failed to reach statistical significance. In contrast, the difference between patients 
with sCAD and healthy volunteers was significant in previous studies 3-5 (Table 2).  
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 Total tHcy levels of the present patients with ischemic stroke due to atherothrombotic or 
small artery disease were similar compared to those of a meta-analysis including 1487 patients 
with ischemic stroke (Table 2) 7. Thus, our findings underscore that patients with ischemic 
stroke have mild hyperhomocysteinemia 7. 
 In conclusion, this study suggest that patients with ischemic stroke due to sCAD have (1) a 
small increase in prevalence of hyperhomocysteinemia compared to healthy volunteers, and the 
prevalence of hyperhomocysteinemia and tHcy levels are lower compared to patients with 
ischemic stroke due to atherothrombotic or small artery disease. The higher prevalence of 
hyperhomocysteinemia in stroke patients with atherothrombotic or small artery disease is 
evident, and explanations have been extensively discussed 7. In contrast, the precise 
pathomechanism of tHcy levels slightly above norm values predisposing to the development of 
sCAD remains undetermined. The small difference in tHcy levels and prevalence of 
hyperhomocysteinemia between healthy volunteers and patients with sCAD might well be an 
artifact. This assumption is underscored by several findings: This study, like previous studies, 
does not have an assessment of tHcy level before stroke onset. Even though the tHcy samples 
are collected soon after the event, there is still time for them to be affected by the stroke. 
Homocysteine has been suggested to be an acute-phase reactant 19,20. Therefore, elevated tHcy 
could rather be the consequence of cerebral ischemia or also an infection which has been shown 
to be associated with sCAD 21,22 than a cause of the disease. Also, food deprivation increases the 
tHcy levels 18,23,24. In acute stroke, patients are kept fasting, and tHcy may, therefore, increase 
independently of the ischemic process. 
 The levels of tHcy increase with age and are higher in men than women 25-28, and latter has 
been reconfirmed in this study. Increasing tHcy levels are not associated with age, and also after 
adjustment, the difference in age between patients with stroke due to sCAD and patients with 
stroke due to atherothrombotic or small artery disease does not account for the different tHcy 
levels observed in the two groups. These results are also in accordance with those of another 
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study in patients with acute ischemic stroke 29, which found no association between tHcy levels 
and gender or age.  
In the present study, patients with stroke due to sCAD were younger, had less vascular risk 
factors and lower tHcy levels compared to those with stroke due to atherothrombotic or small 
artery disease, and had more often a history of migraine with aura (Table 1). The significantly 
higher age of patients with atherothrombotic or small artery disease is the most likely 
explanation of the observed differences in vascular risk factors 30. The higher prevalence of 
migraine with aura in the sCAD patients reflect the observation in three case-control studies that 
migraine was an independent risk factor for sCAD 31. 
In this study, total and LDL cholesterol levels as well as the ratio total / HDL-cholesterol were 
similar in patients with stroke caused by sCAD and atherothrombotic or small artery disease. 
Patients with sICAD causing ischemia have higher cholesterol levels than those without 
ischemia 32 which may explain the surprising lack of difference for cholesterol levels between 
both groups. 
A limitation of the present and also previous studies is the fact that tHcy levels were obtained 
after and not before the onset of stroke or sCAD, which may explain the higher tHcy levels. 
Another limitation is the retrospective nature of the analysis, although the data have been 
collected prospectively. We had to exclude 20% of patients with stroke due to sCAD and 54% 
patients with stroke due to atherothrombotic or small artery disease. A possible explanation 
could be that the patients with sCAD are younger and, thus, referred more rapidly. Another 
limitation is that the vascular risk factors - with the exception of tHcy - were determined by a 
comprehensive clinical screening procedure alone in the healthy subjects. Also, co-factors of the 
tHcy metabolism such as folate, vitamin B6 and B12, were not included in the routine 
investigation and were just measured, if the treating physician deemed it necessary. However, 
previous studies reported that the plasma levels of folate, vitamin B6 and B12 were in the 
 11
normal range in patients with sCAD and did not differ between patients with stroke due to 
sCAD and other causes 3,4.  
In conclusion, this case-control study suggests that patients with ischemic stroke caused by 
sCAD have an increased prevalence of hyperhomocysteinemia compared to healthy subjects, 
but a lower prevalence of hyperhomocysteinemia and lower tHcy levels compared to patients 
with stroke due to atherothrombotic or small artery disease. Mild hyperhomocysteinemia may be 
a risk factor for sCAD causing ischemic stroke, but further studies are needed to identify a 
possible pathomechanism. This study confirms the association of hyperhomocysteinemia with 
ischemic stroke due to atherothrombotic or small artery disease.  
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Table 1  Presenting characteristics of patients with stroke due to spontaneous cervical artery dissection (n=86) and atherothrombotic or small artery disease (n=260), and simple and 
 
multiple† logistic regression models evaluating the association between spontaneous cervical artery dissection and total homocysteine levels 
 
 
 
Spontaneous cervical  
 
Atherothrombotic or 
 
P  
 
Crude models 
 
Adjusted model 
 
 
artery dissection 
 
small artery disease   OR (95% CI) P OR (95% CI) P 
         
 
Male sex [n (%)] 58 (67) 177 (68) 0.913   0.97 [0.58-1.64] 0.913 1.63 [0.59-4.46] 0.344 
 
Mean age ± SD [years] 46.1 ± 10 65.3 ± 11.1 < 0.0001   0.86 [0.84-0.89] 0.000 0.86 [0.83-0.90] 0.000 
 
Smoking actual [n (%)] 30 (35) 91 (35) 0.984   0.99 [0.60-1.66] 0.984 0.37 [0.16-0.86] 0.020 
 
Smoking past 5 years [n (%)] 10 (12) 59 (21) 0.026   0.45 [0.22-0.92] 0.029 0.80 [0.26-2.44] 0.696 
 
Hypertension [n (%)] 22 (26) 190 (73) < 0.0001   0.13 [0.07-0.22] 0.000 0.30 [0.14-0.64] 0.002 
 
Diabetes mellitus type II [n (%)] 1 (1) 38 (15) 0.001   0.07 [0.01-0.51] 0.009 0.10 [0.01-1.44] 0.090 
 
Migraine with aura [n (%)] 10 (12) 8 (3) 0.002   4.14 [1.58-10.87] 0.004 1.18 [0.26-5.22] 0.832 
 
Mean total cholesterol ± SD [mmol/l] 5.51 ± 1.24 5.78 ± 1.31 0.092   0.84 [0.69-1.03] 0.100 1.08 [0.38-3.01] 0.890 
 
Mean HDL cholesterol ± SD [mmol/l] 1.40 ± 0.34 1.55 ± 0.89 0.019   0.71 [0.46-1.09] 0.122 0.11 [0.01-1.34] 0.084 
 
Mean LDL Cholesterol ± SD [mmol/l] 3.56 ± 1.26 3.40 ± 1.16 0.326   1.11 [0.91-1.36] 0.305 2.61 [0.94-7.25] 0.065 
 
Mean ratio total / HDL cholestorol ± SD 4.08 ± 1.49 4.31 ± 1.41 0.204   0.89 [0.74-1.06] 0.191 0.42 [0.20-0.89] 0.024 
 
Mean triglyceride ± SD [mmol/l] 1.59 ± 1.16 1.89 ± 1.24 0.043   0.79 [0.62-1.00] 0.052 1.38 [0.86-2.22] 0.185 
 
Mean homocysteine ± SD [µmol/l] 11.4 ± 3.8 13.6 ± 6.6 0.002   0.92 [0.87-0.97] 0.002 0.89 [0.81-0.98] 0.019 
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Table 1  Presenting characteristics of patients with stroke due to spontaneous cervical artery dissection (n=86) and atherothrombotic or small artery disease (n=260), and simple and 
 
multiple† logistic regression models evaluating the association between spontaneous cervical artery dissection and total homocysteine levels 
 
 
CI denotes confidence interval, OR odds ratio, and SD standard deviation   † regression models were adjusted for 12 covariates (sex, age, current and past smoking, hypertension, 
 
diabetes mellitus, hypercholesterolemia, decreased HDL cholesterol levels, increased LDL cholesterol levels, increased total cholesterol / HDL cholesterol ratio, increased 
 
triglyceride levels, migraine with aura. 
Table 2  Total homocysteine levels in healthy subjects, patients with spontaneous cervical artery dissection with 
 
and without ischemic stroke, and patients with ischemic stroke due to another cause than cervical artery dissection 
 
  
Authors 
 
 
Subjects and 
 
Patients [N] 
 
 
Mean total homocysteine ± SD 
 
(range) [µmol/L] 
 
Healthy subjects  
 
 
Gallai3 
 
30 
 
6.00 ± 0.99 
 Kelly7 2554 11.1 
 Konrad4  95 10.7 ± 3.7 
 Pezzini5 36 8.9 (5-17.3)†
 Soriente33 182 12.5 ± 7.8 
 Present study 100 10.2 ± 3.0 
Patients with sCAD ± stroke Konrad4  95 12.2 ± 4.0 
 Pezzini5 25 13.2 (7.0-32.8)* 
                               and stroke Gallai3 26 17.88 ± 7.99 (5.94-40) 
 Present study 86 11.4 ± 3.8 
Patients with stroke not due to sCAD Kelly7 1487 13.5 
   Pezzini5 31 10.9 † (6-30.2) 
 Soriente33 60 15.8 ± 14.6 
 Present study†
 
260 13.6 ± 6.6 
 
SCAD denotes spontaneous cervical artery dissection 
 
* values indicate median (range)   † ischemic stroke due to atherothrombotic or small artery disease 
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